GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gamida Cell Ltd (OTCPK:GMDAQ) » Definitions » Cash Flow from Operations

Gamida Cell (Gamida Cell) Cash Flow from Operations : $-79.12 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Gamida Cell Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Dec. 2023, Gamida Cell's Net Income From Continuing Operations was $-8.84 Mil. Its Depreciation, Depletion and Amortization was $1.00 Mil. Its Change In Working Capital was $-2.26 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $1.21 Mil. And its Cash Flow from Others was $-7.37 Mil. In all, Gamida Cell's Cash Flow from Operations for the three months ended in Dec. 2023 was $-16.26 Mil.


Gamida Cell Cash Flow from Operations Historical Data

The historical data trend for Gamida Cell's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gamida Cell Cash Flow from Operations Chart

Gamida Cell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial -37.93 -50.22 -81.76 -70.42 -79.12

Gamida Cell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.18 -22.28 -22.00 -18.57 -16.26

Gamida Cell Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Gamida Cell's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Gamida Cell's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-79.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gamida Cell  (OTCPK:GMDAQ) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Gamida Cell's net income from continuing operations for the three months ended in Dec. 2023 was $-8.84 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Gamida Cell's depreciation, depletion and amortization for the three months ended in Dec. 2023 was $1.00 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Gamida Cell's change in working capital for the three months ended in Dec. 2023 was $-2.26 Mil. It means Gamida Cell's working capital declined by $2.26 Mil from Sep. 2023 to Dec. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Gamida Cell's cash flow from deferred tax for the three months ended in Dec. 2023 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Gamida Cell's cash from discontinued operating Activities for the three months ended in Dec. 2023 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Gamida Cell's asset impairment charge for the three months ended in Dec. 2023 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Gamida Cell's stock based compensation for the three months ended in Dec. 2023 was $1.21 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Gamida Cell's cash flow from others for the three months ended in Dec. 2023 was $-7.37 Mil.


Gamida Cell Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Gamida Cell's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Gamida Cell (Gamida Cell) Business Description

Traded in Other Exchanges
N/A
Address
116 Huntington Avenue, 7th Floor, Boston, MA, USA, 02116
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.
Executives
Jeremy Blank director 6446 DREXEL AVENUE, LOS ANGELES CA 90048
Mary Theresa Coelho officer: Chief Financial Officer 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Ronit Simantov officer: CMO & Chief Scientific Officer 1988 CHAPEL STREET, NEW HAVEN CT 06515
Abigail L. Jenkins director, officer: President and CEO C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON MA 02116
Stephen T Wills director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ivan M. Borrello director C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Anat Cohen-dayag director C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Naama Halevi-davidov director C/O KALTURA, INC., 250 PARK AVENUE SOUTH, 10TH FLOOR, NEW YORK NY 10003
Joshua F. Patterson officer: General Counsel C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Bio Medical Investment (1997) Ltd. other: Affiliate of 10% Owner 3 AZRIELI CENTER TRIANGLE, TOWER,, 45TH FLOOR, 132 MENACHEM BEGIN ST., TEL AVIV L3 6702301
Shai Lankry officer: Chief Financial Officer C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Ai Gamida Holdings Llc other: Affiliate of 10% Owner 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Ofer Gonen director 1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102
Clal Biotechnology Industries Ltd. other: Affiliate of 10% Owner 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023
Len Blavatnik 10 percent owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019

Gamida Cell (Gamida Cell) Headlines

From GuruFocus

Q4 2023 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 03-28-2024

Q2 2022 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Q3 2023 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Q3 2020 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Q4 2022 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Gamida Cell BLA Acceptance Call Transcript

By GuruFocus Research 02-07-2024

Q3 2022 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024